SOLIRIS eculizumab (rmc) 300 mg/30 mL concentrated solution for intravenous infusion vial Australija - anglų - Department of Health (Therapeutic Goods Administration)

soliris eculizumab (rmc) 300 mg/30 ml concentrated solution for intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - eculizumab, quantity: 300 mg - injection, intravenous infusion - excipient ingredients: polysorbate 80; sodium chloride; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate monohydrate - soliris is indicated for the treatment of patients with: ? paroxysmal nocturnal haemoglobinuria (pnh) to reduce haemolysis. ? atypical haemolytic uraemic syndrome (ahus). ? adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin-4 (aqp4) antibody-positive. soliris is not intended for acute treatment of a nmosd relapse.

ULTOMIRIS ravulizumab rch 1100 mg in 11 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Australija - anglų - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 1100 mg in 11 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, concentrated - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Australija - anglų - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 300 mg in 3 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

FLEXITOL 50 mg TABLETA DE LIBERACION RETARDADA Peru - ispanų - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

flexitol 50 mg tableta de liberacion retardada

inretail pharma s.a. - droguerÍa - diclofenaco de sodio; - tableta de liberacion retardada - por vial - - diclofenaco

Flexitol Eczema & Dermatitis Lotion Australija - anglų - Department of Health (Therapeutic Goods Administration)

flexitol eczema & dermatitis lotion

lacorium health international pty ltd - oatmeal colloidal, quantity: 20 mg/g - lotion - excipient ingredients: aluminium magnesium silicate; benzyl alcohol; cetostearyl alcohol; ethylhexylglycerin; glycerol; xanthan gum; white beeswax; phenoxyethanol; simmondsia chinensis; medium chain triglycerides; purified water; glyceryl monostearate; glyceryl stearate citrate; sodium hydroxide

STRENSIQ 100 MGML Izraelis - anglų - Ministry of Health

strensiq 100 mgml

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 100 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

STRENSIQ 40 MGML Izraelis - anglų - Ministry of Health

strensiq 40 mgml

alexion pharma israel ltd - asfotase alfa - solution for injection - asfotase alfa 40 mg / 1 ml - asfotase alfa - strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.

"正和"快胃好錠 Taivanas - kinų - 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

"正和"快胃好錠

正和製藥股份有限公司新營廠 台南市新營區嘉芳里新工路２３號 (72004856) - butylscopolamine hbr;;dicyclomine hcl;;chlordiazepoxide hcl;;chlorophyll sodium copper;;aluminum hydroxide hexitol co-dried gel;;magnesium oxide - 錠劑 - butylscopolamine hbr (1208001211) mg; dicyclomine hcl (1208001810) mg; chlordiazepoxide hcl (2824200210) mg; aluminum hydroxide hexitol co-dried gel (5604003201) mg; magnesium oxide (5612001300) mg; chlorophyll sodium copper (8416000640) mg - other drugs for acid related disorders - 胃、十二指腸潰瘍、胃痛、胃酸過多症、胃痙攣、急慢性胃炎

FLEXITOL ECZEMA AND DERMATITIS- oatmeal cream Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

flexitol eczema and dermatitis- oatmeal cream

lacorium health usa inc - oatmeal (unii: 8pi54v663y) (oatmeal - unii:8pi54v663y) - skin protectant temporarily protects and relieves minor skin irritation and itching due to: - eczema - dermatitis - rashes

FLEXITOL HAPPY LITTLE BODIES ECZEMA RELIEF- oatmeal cream Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

flexitol happy little bodies eczema relief- oatmeal cream

lacorium health usa inc - oatmeal (unii: 8pi54v663y) (oatmeal - unii:8pi54v663y) - skin protectant temporarily protects and relieves minor skin irritation and itching due to: - eczema - dermatitis - rashes